{
  "source": "PA-Non-Form-Xalkori.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1364-6\nProgram Non-Formulary\nMedication Xalkori® (crizotinib)*\nP&T Approval Date 7/2021, 2/2022, 4/2022, 4/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nXalkori (crizotinib) is a kinase inhibitor indicated for the treatment of patients with metastatic\nnon-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-\npositive or ROS1-positive as detected by an FDA-approved test. It is also approved for pediatric\npatients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic\nlarge cell lymphoma (ALCL) that is ALK-positive and adult and pediatric patients 1 year of age\nand older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT)\nthat is ALK-positive. The National Cancer Comprehensive Network (NCCN) also recommends\nthe use of Xalkori as a single-agent for the treatment of inflammatory myofibroblastic tumor\n(IMT) with ALK translocation, in treatment of MET-amplification positive NSCLC, MET exon\n14 skipping mutation NSCLC, in treatment of ROS1-positive or ALK-positive brain metastases\nfrom NSCLC, in histiocytic neoplasms that are positive for ALK rearrangement, and in metastatic\nor unresectable cutaneous melanoma that is ROS1 gene fusion-positive as second-line or\nsubsequent therapy for disease progression, intolerance, and/or projected risk of progression with\nBRAF-targeted therapy.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the notification\ncriteria.\n2. Coverage Criteriaa:\nA. Patients ",
    "tates also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the notification\ncriteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Xalkori* will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Inflammatory Myofibroblastic Tumor (IMT)\n1. Initial Authorization\na. Xalkori will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(1) Diagnosis of inflammatory myofibroblastic tumor (IMT) with ALK translocation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Xalkori will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Xalkori therapy\nAuthorization will be issued for 12 months.\nC. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Xalkori* will be approved based on all of the following criteria:\n(1) Diagnosis non-small cell lung cancer (NSCLC)\n-AND-\n(2) Disease is one of the following:\n(a) Metastatic\n(b) Recurrent\n(c) Advanced\n-AND-\n(3) One of the following:\n(a) Tumor is ROS1-positive\n(b) Tumor is positive for mesenchymal-epithelial transition (MET) amplification\n(c) Tumor is positive for MET exon 14 skipping mutation\n(d) Both of the following:\ni. Tumor is anaplastic lymphoma kinase (ALK)-positive\n-AND-\nii. One of the following:\n• Provider attests the patient has a contraindication, history of\nintolerance, or that the patient is not an appropriate candidate\n(document reason) to all of the following therapies:\nAlecensa (alectinib)\no\nAlunbrig (brigatinib)\no\nLorbrena (lorlatinib)\no\n© 2025 UnitedHealthcare Services, Inc.\n2\n-OR-\n• Both of the following:\nPatient is currently on Xalkori therapy\no\n-AND-\nPatient has not received a manufacturer supplied sample at no cost\no\nfrom a prescriber’s office, or any form of assistance from the\nPfizer Oncology Together™ program (e.g. sa",
    "n Xalkori therapy\no\n-AND-\nPatient has not received a manufacturer supplied sample at no cost\no\nfrom a prescriber’s office, or any form of assistance from the\nPfizer Oncology Together™ program (e.g. sample card which can\nbe redeemed at a pharmacy for a free supply of medication) or a 30\nday free trial from a pharmacy as a means to establish as a current\nuser of Xalkori*\n*Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\nthe Pfizer Oncology Together™ program shall be required to meet initial authorization criteria as\nif patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Xalkori will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Xalkori therapy\nAuthorization will be issued for 12 months.\nD. Central Nervous System (CNS) Cancers\n1. Initial Authorization\na. Xalkori will be approved based on both of the following criteria:\n(1) Diagnosis of metastatic brain cancer from NSCLC\n-AND-\n(2) One of the following:\n(a) Tumor is anaplastic lymphoma kinase (ALK)-positive\n(b) Tumor is ROS1-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Xalkori will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services, Inc.\n3\n(1) Patient does not show evidence of progressive disease while on Xalkori therapy\nAuthorization will be issued for 12 months.\nE. Anaplastic Large Cell Lymphoma\n1. Initial Authorization\na. Xalkori will be approved based on all of the following criteria:\n(1) Diagnosis of anaplastic large cell lymphoma\n-AND-\n(2) Tumor is anaplastic lymphoma kinase (ALK)-positive\n-AND-\n(3) Disease is relapsed or refractory\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Xalkori will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive dise",
    "lapsed or refractory\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Xalkori will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Xalkori therapy\nAuthorization will be issued for 12 months.\nF. Histiocytic Neoplasms\n1. Initial Authorization\na. Xalkori will be approved based on all the following criteria:\n(1) Diagnosis of one of the following:\n(a) Langerhans Cell Histiocytosis\n(b) Erdheim-Chester Disease\n(c) Rosai-Dorfman Disease\n-AND-\n(2) Disease is positive for ALK rearrangement\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n4\n2. Reauthorization\na. Xalkori will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Xalkori therapy.\nAuthorization will be issued for 12 months.\nG. Melanoma\n1. Initial Authorization\na. Xalkori will be approved based on all of the following criteria:\n(1) Diagnosis of metastatic or unresectable cutaneous melanoma\n-AND-\n(2) Disease is ROS1 gene fusion-positive\n-AND-\n(3) Used as second-line or subsequent therapy for disease progression, intolerance,\nand/or projected risk of progression with BRAF-targeted therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Xalkori will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Xalkori therapy\nAuthorization will be issued for 12 months.\nH. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na Coverage of oncology medications may be approved based on state mandates.\n*Xalkori is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer to\nplan specifics to determine exclusion status.\n© 2025 United",
    "ay be approved based on state mandates.\n*Xalkori is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer to\nplan specifics to determine exclusion status.\n© 2025 UnitedHealthcare Services, Inc.\n5\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Xalkori [package insert]. New York, NY: Pfizer Labs.; September 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed January 2,\n2025.\nProgram Non-Formulary - Xalkori (crizotinib)\nChange Control\n7/2021 New program.\n2/2022 Removed “Prior Authorization” from program title and kept Non-\nFormulary. Updated background and references. Added clinical\ncriteria for histiocytic neoplasms that are positive for ALK\nrearrangement.\n4/2022 Added oncology medications state mandate note.\n4/2023 Annual review with no change to clinical criteria. Updated background\nand references.\n2/2024 Annual review. Updated background and coverage criteria for\ncutaneous melanoma per NCCN. Updated references.\n2/2025 Annual review with no change to clinical criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n6"
  ]
}